Incyte conducts Phase 2 Clinical Trials for Myelofibrosis and Essential Thrombocythemia

Myelofibrosis A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of INCB050465 and ruxolitinib in subjects with myelofibrosis Talk to your doctor if you are interested in participating […]

David Wallace, PV Reporter honored with 2016 Cure Magazine MPN Hero Award

Our Third Year attending the MPN Heroes Program by David Wallace For the past 4 years, Cure Magazine and Incyte Corporation have recognized leaders within the MPN community with the MPN Hero award.  The two categories include commitment to the individual or community.  I am honored to receive this award for “commitment to the broader […]

Gary Vogt’s Rollercoaster Ride with Myelofibrosis

Publisher’s Intro by David Wallace I met Gary and Kathy Vogt by sheer coincidence while taking the shuttle bus from the San Francisco airport to our downtown hotel, in early December 2014.  We were there for the MPN Heroes Award Event, while I was also covering the ASH conference for PV Reporter. Numerous things struck […]

Jakafi One Step Closer to Approval for Polycythemia Vera

Jakafi Improves Symptoms in PV In phase 3 randomized controlled trial, Jakafi (ruxolitinib) improved several key symptoms in polycythemia vera, according to Dr Srdan Verstovsek of MD Anderson Cancer Center in Houston. Results from the RESPONSE trial were presented at the 2014 ASCO (American Society of Clinical Oncology) annual meeting in Chicago.  PV is a […]

 
error: Content is protected !